LUND, Sweden, April 21, 2022 /PRNewswire/ -- Immunovia will
publish its first quarter 2022 results on April 28, 2022 at 8:00 am
CET. Analysts, investors and media are invited to a webcast
teleconference on the same day at 13:00 pm
CET. The report together with the presentation slides will
be available at www.immunovia.com
Philipp Mathieu, Acting CEO and
President, and Karin Almqvist Liwendahl, CFO, will present on
Immunovia's development. The presentation will be held in English
and be followed by a Q&A session. You are welcome to join via
webcast or phone, see details below.
Telephone numbers and webcast
Ring any of the numbers below to participate via telephone. Please
dial in a few minutes before the presentation starts.
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06
13
United States: +1 631 570 56
13
Link to the
webcast: https://creo-live.creomediamanager.com/c062bfe9-6671-4cee-a51a-3ed5d85ca715
To ask questions, it is necessary to dial in. A recording of the
presentation will be available on Immunovia's website.
For more information, please contact:
Tobias Bülow
Senior Director Investor Relations and Corporate Communications
tobias.bulow@immunovia.com
+46 736 36 35 74
The information was submitted for publication on April 21, 2022, at 10:30
am CET.
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-immunovia-s-q1-presentation,c3550030
The following files are available for download:
https://mb.cision.com/Main/13121/3550030/1566840.pdf
|
Press release
(PDF)
|